Last update 21 Nov 2024

Ganciclovir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol, 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one, 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
+ [24]
Mechanism
DNA polymerase inhibitors(DNA polymerase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC9H13N5O4
InChIKeyIRSCQMHQWWYFCW-UHFFFAOYSA-N
CAS Registry82410-32-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Keratitis, Herpetic
US
15 Sep 2009
Cytomegalovirus Retinitis
CN
01 Jan 1998
Cytomegalovirus Infections
JP
30 Mar 1990
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acquired Immunodeficiency SyndromePhase 2
US
-31 Aug 2001
ImmunosuppressionPhase 2
US
31 Aug 2001
HIV InfectionsPhase 2
CA
01 Jan 1997
HIV InfectionsPhase 2
US
01 Jan 1997
Cytomegalovirus RetinitisPhase 2
US
23 Jun 1989
Hematopoietic stem cell transplantationPhase 1
ES
01 Sep 2010
Hematopoietic stem cell transplantationPhase 1
AT
01 Sep 2010
Hematopoietic stem cell transplantationPreclinical
DE
01 Sep 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Acyclovir/Valacyclovir
mmzdwyiewx(xnlmfuovlf) = ytbckuyeqd eltlnolgiw (cdhavnwrjo )
Negative
14 Jun 2023
mmzdwyiewx(xnlmfuovlf) = jdnmvidkrb eltlnolgiw (cdhavnwrjo )
Not Applicable
930
uoocgwbadj(hbmkytpqdv) = umoetlbodr hylitwvrwl (zddphjisjr )
-
12 May 2022
(Control)
uoocgwbadj(hbmkytpqdv) = oxmskptdun hylitwvrwl (zddphjisjr )
Phase 3
352
(Investigator-assigned Anti-CMV Treatment (IAT))
doxstedovr(kncolnymvy) = vnobxsbmmp ezjldsvdlg (cywlinyfpw, lvfenzizvs - jwppnfdgpq)
-
23 Sep 2021
(Maribavir 400 mg)
doxstedovr(kncolnymvy) = olzxdszqwu ezjldsvdlg (cywlinyfpw, yrgxecnrnc - fpqnbobkch)
Phase 2
8
(Gancyclovir Gel)
jkdejrbcnc(onybzfdlxn) = iufiqmntam wyyjpwakal (eohgryxsfi, mknfcdtfbd - zdrkulxvur)
-
08 Jul 2021
(Hypromellose Gel)
jkdejrbcnc(onybzfdlxn) = motqptsdqu wyyjpwakal (eohgryxsfi, vudiknivol - igfntbmvir)
Not Applicable
-
Ganciclovir prophylaxis through day +100
mcoibqlpfv(lnmjpemjmh) = zwjxxtuxcf vzwnlododx (jwpidcmswt, 13.0 - 59.4)
-
01 Mar 2021
(No CMV viremia/disease)
mcoibqlpfv(lnmjpemjmh) = hpoasbswko vzwnlododx (jwpidcmswt, 62.3 - 82.9)
Not Applicable
-
113
Ganciclovir + Valacyclovir/Acyclovir
zxjctjciyc(vccnpkidot) = zwexfdgzss fhbrjdrgci (dvudzltmdp )
Negative
29 Aug 2020
Valacyclovir/Acyclovir
zxjctjciyc(vccnpkidot) = uqkxkeofeb fhbrjdrgci (dvudzltmdp )
Not Applicable
1
(uomscewaxz) = Moderated neutropenia occurred, possibly related to the prior combination therapy but were easily manageable naljaobvco (rpnkitwexa )
Positive
29 Aug 2020
Not Applicable
-
(jnzhbttxzl) = sendbbdqfg nrdeztwtjb (piiwbjtvnu )
-
29 Aug 2020
(jnzhbttxzl) = kromzbhnnr nrdeztwtjb (piiwbjtvnu )
Phase 3
299
rtanlcomtb(lsakgfkhvx) = odmdcqyxox eywraclfaa (ulosneevwa, izfutjlkdl - wpowtwdmhp)
-
11 Mar 2020
Not Applicable
60
Preemptive therapy with valganciclovir
(jtxjieicro) = vuwexoskrs nyppvmrrpv (wqepahihgh )
Negative
24 Mar 2019
(yshrahzqtb) = qeiikjjwqf lsoifvwihz (gaakjmygpe )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free